Taken together, these results suggest that MAPK signaling upon NF1 knockout in neuroblastoma cells harboring ALK mutations is associated with loss of negative ERK-RAF feedback, leading us to hypothesize that these cell lines may be particularly sensitive to MEK inhibitor treatment. This evidence concerns the gene MAP2K7 and neuroblastoma.